Tourmaline Bio
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2002-01-01
- Employees
- 44
- Market Cap
- $428.2M
- Website
- http://www.tourmalinebio.com
- Introduction
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.
Tourmaline Bio's Heart Disease Antibody Shows Promise in Phase 2, But Shares Fall Amid Competition Concerns
Tourmaline Bio's antibody drug pacibekitug demonstrated significant reduction in cardiovascular risk biomarkers compared to placebo in Phase 2 trials, but shares fell 18% as investors question its competitive edge against Novo Nordisk's offering.
TEPEZZA Sales Surge as Thyroid Eye Disease Treatment Market Expands to $2.3 Billion
TEPEZZA, the first FDA-approved treatment for thyroid eye disease, generated $1.9 billion in sales for 2024, with $460 million in Q4 alone, addressing a critical unmet need for patients with limited treatment alternatives.
Tourmaline Bio Advances Pacibekitug Program with Expanded Cardiovascular Focus
Tourmaline Bio's Phase 2 TRANQUILITY trial, assessing pacibekitug in chronic kidney disease patients with elevated C-reactive protein, has exceeded its enrollment target, with topline data expected in Q2 2025.